摘要
目的观察甲磺酸阿帕替尼治疗骨肉瘤的临床疗效。方法18例手术和(或)化疗失败的骨肉瘤患者均给予甲磺酸阿帕替尼500mg·d^-1,早餐后口服,并观察临床疗效和不良反应发生情况。结果甲磺酸阿帕替尼治疗骨肉瘤的有效率为16.7%,疾病控制率为55.6%,中位疾病无进展生存时间为4.1个月,中位总生存时间为8个月。甲磺酸阿帕替尼的主要不良反应为高血压(77.8%)、手足综合征(72.2%)、蛋白尿(44.4%),消化道反应(50.0%),多为Ⅰ、Ⅱ级,未见Ⅳ级不良反应。结论甲磺酸阿帕替尼对骨肉瘤疗效确切,安全性较高,值得临床进一步推广应用。
Objective To observe the clinical efficacy of apatinib mesylate in the treatment of patients with osteosarcoma. Methods Eighteen patients with osteosarcoma failed surgery and (or)chemotherapy received apatinib mesylate 500 mg·d^-1 after breakfast, and the efficacy and toxicities were evaluated. Results The response rate of apatinib mesylate was 16.7%, and the disease control rate was 55.6%in the treatment of osteosarcoma.The median progression-free survival time was 4.1 months, and the overall survival time was 8 months. The main toxicities of apatinib mesylate were hypertension (77.8%), hand-foot syndrome (72.2%), proteinuria (44.4%), digestive tract reaction (50.0%), and the toxicities were mostlygrade Ⅰ and Ⅱ, no toxicities with grade Ⅳ toxicities were observed. Conclusion Apatinib mesylate is effect and safe for patients with osteosarcoma.
作者
冯俊岭
马欣然
张明智
FENG Junling;MA Xinran;ZHANG Mingzhi(Department of Hematology and Oncology,Xiping People’s Hospital,Zhumadian 463900,China;Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《肿瘤基础与临床》
2019年第3期220-222,共3页
journal of basic and clinical oncology
